GlassScriptPhysician profile
Jamie A Smith
NPI 1124363874
$2,962.00
in general payments reported to CMS, 2019-2025
19 companies · $749 in 2025
The $749 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $523 · 2023: $580 · 2024: $668 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $746.45 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $505.18 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $240.62 | 2021-2025 | Caplyta |
| Indivior INC. | $190.97 | 2022-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $189.66 | 2021-2025 | Invega Sustenna |
| Alkermes, INC. | $176.34 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $142.22 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $131.76 | 2021-2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $119.63 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $116.36 | 2022-2025 | Fanapt, Hetlioz |
| Avadel Cns Pharmaceuticals, LLC | $92.87 | 2025 | Lumryz |
| Lundbeck LLC | $83.84 | 2021-2024 | Abilify Maintena |
| Abbvie INC. | $67.70 | 2021-2023 | |
| Harmony Biosciences LLC | $33.64 | 2025 | |
| Abbott Laboratories | $32.37 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $25.77 | 2025 | Quviviq |
| Supernus Pharmaceuticals, INC. | $24.94 | 2022 | |
| Axsome Therapeutics, INC. | $23.49 | 2025 | Auvelity |
| Medtronic, INC. | $18.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.